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Aims: This study aimed to compare the performance of Positive and Negative Syndrome Scale (PANSS) symptom
severity criteria established by the Remission in Schizophrenia Working Group (RSWG) with criteria based on Clinical
Global Impression (CGI) severity score. The 6-month duration criterion was not taken into consideration.
Methods: A convenience sample of 112 chronic psychotic outpatients was examined. Symptomatic remission was
evaluated according to RSWG severity criterion and to a severity criterion indicated by the overall score obtained at
CGI-Schizophrenia (CGI-SCH) rating scale (≤3) (CGI-S).
Results: Clinical remission rates of 50% and 49.1%, respectively, were given by RSWG and CGI-S, with a significant
level of agreement between the two criteria in identifying remitted and non-remitted cases. Mean scores at
CGI-SCH and PANSS scales were significantly higher among remitters, independent of the remission criteria
adopted. Measures of cognitive functioning were largely independent of clinical remission evaluated according to
both RSWG and CGI-S. When applying RSWG and CGI-S criteria, the rates of overall good functioning yielded by
Personal and Social Performance scale (PSP) were 32.1% and 32.7%, respectively, while the mean scores at PSP scale
differed significantly between remitted and non-remitted patients, independent of criteria adopted. The proportion
of patients judged to be in a state of well-being on Social Well-Being Under Neuroleptics-Short Version scale
(SWN-K) were, respectively, 66.1% and 74.5% among remitters according to RSWG and CGI-S; the mean scores at
the SWN scale were significantly higher only among remitters according to CGI-S criteria.
Conclusions: CGI severity criteria may represent a valid and user-friendly alternative for use in identifying patients
in remission, particularly in routine clinical practice.Introduction
Clinical remission [1] is viewed nowadays as an achie-
vable goal in the treatment of schizophrenia and related
disorders, with sustained remission representing one of
the main steps involved in achieving recovery [2]. The
lack of a univocal method for assessing remission has
long represented a major methodological problem, par-
ticularly due to the largely different set of criteria used in
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unless otherwise stated.type of rating scales adopted and time-points considered
in defining remission [3]. A significant step forward was
made following publication of the Remission in Schizo-
phrenia Working Group criteria (RSWGcr) [4]. These cri-
teria establish clinical remission based on a symptom
severity criterion comprising several crucial items from
some of the most relevant rating scales used in schizo-
phrenia (Positive and Negative Syndrome Scale (PANSS),
Brief Psychiatric Rating Scale (BPRS), SANS, SAPS); with
particular regard to PANSS, eight items were identified as
the most diagnostic-specific for schizophrenia (i.e. they
accounted for core symptoms necessary for a diagnosis ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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criterion of 6 months was introduced. As PANSS scale
provides ratings that investigate not only symptom sever-
ity per se but also functional impairment, a score of “mild”
or better (i.e. 3 points or less) at all eight “core” symptoms
was considered sufficiently representative of a level of im-
pairment consistent with symptomatic remission of the
disorder [4]. The validity and utility of the cross-sectional
symptom and time criteria were evaluated [5,6], and both
were found to be clinically meaningful in evaluating re-
mission [7,8]. However, symptom severity was the only
criterion adopted in the majority of studies [9], in spite of
criticism that this may inflate rates of remission detected.
RSWG criteria have proved to be conceptually viable and
easy to use both in clinical trials and clinical practice [10];
however, as the use of PANSS or BPRS rating scales in
routine practice is time-consuming and linked to the
knowledge of specific skills by clinicians, the need for
simpler and easier means of evaluating remission is high-
lighted. Accordingly, Leucht et al. [11] proposed use of
the Clinical Global Impression Scale in pragmatic trials,
while Masand et al. [3] demonstrated that Clinical Global
Impression (CGI)-Improvement score is a valid proxy
measure for remission in schizophrenia. Starting from
these premises, the present study was designed to evaluate
the efficacy of a Clinical Global Impression-Schizophrenia
(CGI-SCH) Severity score equal to or lower than 3 as a
measure of remission in comparison to PANSS-based
RSWG criteria [4]. In particular, clinical remission was
evaluated according to functional status, quality of life
and cognitive outcomes [12].
Materials and methods
Sample
In the context of a prospective study [13], a convenience
sample comprising all chronic outpatients with a diagno-
sis of schizophrenia or schizoaffective disorder according
to DSM-IV-TR attending a university community mental
health centre (CMHC) in the year 2010 was recruited
consecutively. Patients with other comorbid psychiatric
disorders, including substance use disorders, and/or som-
atic disorders were also included in the study. Patients af-
fected by comorbid mental retardation or organic brain
diseases were excluded from the study. Standard care rou-
tinely available in Italian CMHCs was provided (clinical
monitoring at least on a monthly basis; pharmacological
treatment; home care when required, psychosocial and re-
habilitation interventions tailored to patient’s needs).
Ratings
The study was approved by the Ethics Committee of Local
Health Unit n.8, Cagliari and was performed in compli-
ance with national laws. Evaluation was performed by resi-
dents in psychiatry using a set of standardized methods,after adequate training in use of all instruments adopted.
Clinical ratings for each single patient were generally
carried out by different residents whenever possible.
Patients were interviewed by means of the SCID-I [14]
and SCID-II [15], after providing informed consent. In-
terviews were conducted by residents in psychiatry trained
in use of the instruments; inter-rater reliability, assessed
using Cohen’s K before the study, was higher than 0.80.
Personal and social data and clinical history were collected
through a structured interview purpose-developed for the
study and from standardized records routinely used in the
centre and based on procedures suggested by the Associ-
ation for Methodology and Documentation in Psychiatry
(AMDP) [16], as described in previous studies [17,18].
Symptom severity was evaluated using PANSS [19]. Inter-
views were conducted by residents in psychiatry trained in
use of the instrument; inter-rater reliability of PANSS
evaluations in terms of intraclass correlation coefficient
(ICC) for PANSS total score ranged from 0.65 to 0.95.
RSWG criteria [4] based on ratings at eight focal symp-
toms in positive, negative and general psychopathology
subscales of PANSS (P1, P2, P3, N1, N4, N6, G5, G9) were
applied for clinical remission. Patients were judged to
be in clinical remission according to a severity criterion
(scores obtained at each item ≤3 points, indicating mild
severity of symptoms). Due to the cross-sectional nature
of the study, clinical remission was evaluated taking into
account the severity criterion alone, excluding the dur-
ation criterion (remission maintained for 6 months).
Clinical status was also evaluated by the CGI-SCH [20]
by residents in psychiatry trained in use of the instru-
ment. Inter-rater reliability of CGI-SCH evaluations in
terms of ICC for CGI-SCH total score ranged from 0.69
to 0.96; the criterion suggested by Leucht et al. [11], indi-
cating a severity score equal to or lower than 3 (slightly ill)
to indicate remission, was used. When applying PANSS,
remission was evaluated excluding the 6-month criterion
even when CGI-SCH was evaluated. Cognitive functio-
ning was evaluated by means of the Brief Assessment of
Cognition in Schizophrenia scale (BACS) [21] for which a
gender/age/education-adjusted score and thus an equiva-
lent score were calculated [22]. Mini Mental State Exam-
ination (MMSE) test [23] was administered to calculate an
age/education-adjusted score [24]. Functioning was evalu-
ated by Personal and Social Performance scale (PSP) [25],
to assess social functioning of patients in four main
areas: socially useful activities, personal and social rela-
tionships, self-care and disturbing/aggressive behaviours.
A comprehensive overall score ranging from 1 (maximum
dysfunction) to 100 (maximum functioning) was attrib-
uted, based on score obtained at each single area. A total
score exceeding 70 indicates a condition of “functional re-
mission”, i.e. an overall good functioning. Subjective well-
being was evaluated by means of Subjective Well-Being
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administered 20-item rating scale aimed at assessing the
psychological and physical well-being of patients treated
with neuroleptics. An overall score equal to or higher than
80 indicates a state of subjective well-being.
Statistical analysis
Categorical data were analyzed using Pearson’s χ2 test or
Fisher’s exact test; continuous variables were assessed by
means of Student’s t test for independent samples. The
magnitude of differences in mean scores obtained at dif-
ferent rating scales used in the study was calculated by
means of Cohen’s d. To evaluate differences in remission
rates observed according to the different proposed cri-
teria, McNemar’s test for matched pairs of subjects was
used. Phi coefficient was used to evaluate correlations
between rates of remission evaluated by means of RSWG
criteria and CGI-Severity criteria Data analyses were per-
formed using SPSS 19.0. Level of significance was set at
a p value ≤0.05 for two-tailed hypothesis.
Results
Baseline characteristics
The sample comprised 112 patients, 80 (71.4%) males
and 32 (28.6%) females and 46 (41.1%) schizophrenic
and 66 (58.9%) schizoaffectives; 35 patients (31.3%) were
affected by comorbid medical illnesses and 32 (28.5%) by
comorbid substance abuse disorders; the mean age was
43.5 ± 9.42 years (range 25–68); mean years of education
10.84 ± 3.9 (range 4–24); 97 subjects (86.6%) were single;
83 (74.1%) unemployed.
Clinical remission
A similar proportion of remitted patients was obtained
using both RSWG criteria (n = 56, 50%) and CGI-Severity
criteria (n = 55, 49.1%) (p = 1.000). According to RSGW,
43.5% of schizophrenics (n = 20) and 54.5% of schizoaf-
fectives (n = 36) were “remitted” (p = 0,249), while the
proportion of “remitted” patients according to CGI cri-
teria was 52% (N = 24) and 47% (n = 31), respectively,
for patients affected by schizophrenia and schizoaffectiveTable 1 Sociodemographic characteristics of remitted and no
Items Criteria of remission
Education (years) (means ± SD) SWGC
CGI-S
Occupation (unemployed) N (%) SWGC
CGI-S
Course of illness (continuous + episodic
with residual symptoms) N (%)
SWGC
CGI-S
Duration of illness (months) (means ± SD) SWGC
CGI-S
SWGC Schizophrenia Working Group Severity Criterion, CGI Clinical Global Impressiodisorder (p = 0.588). From the total sample, 37.5% (n = 42)
were found to be in remission and 38.4% (n = 43) non-
remitted according to both RSWG and CGI-S criteria
(Phi = 0.518, p < .0001). No significant differences in re-
mission rates, using either RSWG or CGI criteria, were
found between patients both with and without comorbid
medical illnesses or substance use disorders. Remitted pa-
tients featured several significantly different characteris-
tics, independent of remission criteria adopted, as shown
in Table 1. Mean scores at CGI-SCH and PANSS were all
significantly higher among non-remitted patients yielding
effects of medium (Cohen’s d 0.5–1) or large (Cohen’s
d > 1) magnitude for the majority of scales, independent
of remission criteria (Table 2). Similar results were found
on considering schizophrenic and schizoaffective patients
separately. Indeed, mean scores at CGI-SCH and PANSS
were significantly higher (all p values ranging between
<0.002 and <0.0001) among non-remitted schizophrenic
and schizoaffective patients, independent of remission cri-
teria used. The only exception was represented by CGI-
SCH-Cognitive symptoms scale, revealing no significant
differences in mean scores obtained by both groups, inde-
pendent of remission criteria adopted.
Cognitive functioning
Both RSWG and CGI-S criteria detected very similar
mean scores for cognitive functioning (Table 3) between
remitters and non-remitters, with the sole exception of
MMSE, featuring higher scores among remitters for
RSWG criteria, and BACS-Digit sequencing task, with
significantly higher scores among remitters using both
RSWG and CGI-S criteria. Considering separately the
two diagnostic subgroups, significantly higher scores were
found for Fluency/category instances (p = 0.003) and
Verbal Fluency/Controlled Oral Words association test
(p = 0.010) among schizophrenics judged as remitted ac-
cording to RSWG criteria and for Verbal Fluency/Con-
trolled Oral Words association test (p = 0.045) among
schizophrenics judged as remitted according to CGI
criteria. In schizoaffective patients, significantly higher
mean scores were found only for Digit sequencing task,n-remitted patients according to different criteria
Remitted Non-remitted Statistics (df)
11.55 (4.16) 10.13 (3.43) t(110) = 1.981 p = .050
11.55 (4.01) 10.16 (3.62) t(110) = 1.922 p < .057
36 (64.3%) 47 (83.9%) Chisq(1) = 9.775 p < .0001
35 (63.3%) 48 (84.2%) Chisq(1) = 6.175 p = .013
39 (69.6%) 50 (89.3%) Chisq(1) = 9.560, p = .008
36 (65.5%) 53 (92.9%) Chisq(1) = 23.343 p < .0001
163.68 (100.01) 227.48 (112.58) t(110) = −3.171, p = .002
173.04 (106.72) 217.33 (111.11) t(110) = −2.151, p = .034
n Severity Criterion.
Table 2 Mean scores ± sd at clinical scales of remitted and non-remitted patients according to different criteria
Items Criteria of remission Remitted Non-remitted Statistics (df)/p Cohen’s d
CGI-S positive symptoms SWGC 1.60 (0.95) 2.95 (1.42) t(110) = −5.853, p < .0001/−1.17
CGI-S 1.49 (0.84) 3.07 (1.37) t(110) = −7.316, p < .0001/−1.39
CGI-S negative symptoms SWGC 1.78 (0.91) 3.36 (1.27) t(110) = −7.478, p < .0001/−1.43
CGI-S 1.80 (0.87) 3.39 (1.36) t(110) = −7.326, p < .0001/−1.39
CGI-S depressive symptoms SWGC 1.71 (0.85) 2.36 (1.31) t(110) = −3.076, p = .003/−0.58
CGI-S 1.53 (0.716) 2.61 (1.40) t(110) = −5.148, p = .0001/−0.98
CGI-S cognitive symptoms SWGC 1.84 (1.03) 3.18 (1.20) t(110) = −6.298, p < .0001/−1.19
CGI-S 1.85 (1.08) 3.14 (1.88) t(110) = −5.999, p < .0001/−1.14
CGI-S overall severity SWGC 2.45 (0.95) 3.82 (0.76) t(110) = −8.309, p < .0001/−1.59
CGI-S 2.24 (0.66) 4.07 (0.65) t(110) = −14.74, p < .0001/−2.81
PANSS positive scale SWGC 8.96 (2.09) 14.39 (4.35) t(110) = −8.417, p < .0001/−1.59
CGI-S 9.55 (2.70) 13.74 (4.67) t(110) = −5.788, p < .0001/−1.10
PANSS negative scale SWGC 10.57 (3.65) 18.70 (5.85) t(110) = −8.803, p < .0001/−1.66
CGI-S 10.96 (3.68) 18.18 (6.39) t(110) = −7.287, p < .0001/−1.39
PANSS general psychopathology SWGC 21.98 (4.87) 32.68 (7.48) t(110) = −8.964, p < .0001/−1.69
CGI-S 22.51 (4.83) 31.98 (8.25) t(110) = −7.378, p < .0001/−1.41
PANSS total scale SWGC 41.52 (7.92) 65.77 (13.87) t(110) = −11.35, p < .0001/−1.69
CGI-S 43.02 (8.82) 63.89 (15.87) t(110) = −8.559, p < .0001/−1.63
SWGC Schizophrenia Working Group Severity Criterion, CGI Clinical Global Impression Severity Criterion.
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Functioning
Twenty-three patients (20.5%), particularly 13% of schi-
zophrenics (n = 6) and 25.8% of schizoaffectives (n = 17)
(p = 0.101) were found to be in functional remission.
The proportion of “functionally remitted” patients who
were clinically remitted according to RSWG criteria wasTable 3 Mean score ± sd at neuropsychological tests in remitte
Items Criteria of remission
MMSE total score SWGC
CGI-S
BACS list learning SWGC
CGI-S
BACS Digit sequencing task SWGC
CGI-S
BACS Verbal Fluency/category instances SWGC
CGI-S
BACS Verbal Fluency Controlled Oral Words ass.test SWGC
CGI-S
BACS Symbol coding SWGC
CGI-S
BACS Tower of London SWGC
CGI-S
SWGC Schizophrenia Working Group Severity Criterion, CGI Clinical Global Impressio15% (n = 3) for schizophrenics (p = 0.730) and 41.7% for
schizoaffectives (n = 15) (p = 0.001); CGI criteria indi-
cated proportions of 20.8% (n = 5) and 41.9% (n = 13),
respectively, for schizophrenics (p = 0.101) and schizo-
affectives (p = 0.05). Overall, the rates of “functionally”
remitted patients judged also to be in clinical remission
according to RSWG and CGI-S criteria were 32.1%
(n = 18) and 32.7% (n = 18), respectively. On the contrary,
rates of non-“functionally” remitted patients also deemedd and non-remitted patients according to different criteria
Remitted Non-remitted Statistics (df)/p Cohen’s d
26.80 (2.71) 25.02 (4.42) t(110) = 2.576, p = .011/0.485
26.40 (3.20) 25.44 (4.21) t(110) = 1.358, p = .177/NA
9.31 (4.77) 9.92 (4.59) t(99) = −.652, p = 0.516/NA
9.51 (4.78) 9.70 (4.53) t(101) = .199, p = 0.843/NA
14.75 (6.06) 11.26 (6.19) t(99) = 2.86, p = .005/0.571
15.37 (5.56) 10.34 (6.13) t(101) = 4.363, p < .0001/0.868
9.89 (4.98) 8.10 (4.96) t(99) = 1.801, p = .075/NA
9.63 (5.07) 8.25 (4.84) t(101) = 1.405, p = .163/NA
15.05 (3.89) 14.50 (5.49) t(99) = 0.569, p = .571/NA
15.47 (4.61) 13.98 (4.75) t(101) = 1.613, p = .110/NA
32.60 (13.64) 28.60 (12.29) t(99) = 1.549, p = 0.125/NA
31.84 (13.03) 28.71 (13.15) t(101) = 1.214, p = .228/NA
11.38 (5.98) 9.5 (6.53) t(99) = 1.445, p = 0.152/NA
10.96 (6.20) 9.77 (6.27) t(101) = .969, p = .228/NA
n Severity Criterion, NA not assessed in the absence of significant difference.
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(n = 52) and 91.1% (n = 51). Phi coefficients were 0.287
(p = .002) and 0.296 (p = .002), respectively, using RSWG
and CGI-S criteria. Significantly higher mean scores at
PSP subscales and significantly lower ones at PSP total
scale were found among non-remitters, indicating poorer
functioning (Table 4), independent of remission criteria
adopted. The sole exception was observed for PSP self
care and PSP aggressive-disturbing behaviour, where dif-
ferences in mean scores, although lower, did not differ sig-
nificantly when using CGI-S criteria to evaluate remission;
a similar magnitude of effect sizes was revealed between
the clinically remitted according to RSWG and CGI-S cri-
teria. Considering the two groups of patients separately,
we found that for schizophrenics, mean scores at PSP-
socially useful activities subscale were significantly higher
among patients judged to be in clinical remission using
both SWGC and CGI criteria (respectively, p = 0.012 and
p = 0.002). Mean scores obtained at PSP-personal rela-
tionships and PSP-total scores were significantly higher
only among clinical “remitters” according to CGI criteria
(p = 0.002 and p < 0.0001, respectively); no significant dif-
ferences were found in mean scores at PSP-aggressive/
disturbing behaviours and PSP-Self-care subscales, in-
dependent of the criterion adopted for evaluating clin-
ical remission. Significantly higher scores were obtained
for clinically remitted schizoaffective patients according
to RSWG criteria at all PSP subscales and PSP-total
score (all values between p < 0.005 and p < 0.0001). Apply-
ing CGI criteria, mean scores were significantly higher at
PSP-Socially useful and Personal relationships subscales
and PSP-Total score (all values p < 0.0001), while no sig-
nificant difference was found at PSP-aggressive/disturbing
behaviour and PSP-Self-care subscales.
Subjective well-being
Seventy-one patients (63.4%) were found to be in a state
of “well-being”, in particular 69.6% of schizophrenicsTable 4 Results at PSP scale in remitted and non-remitted pa
Items Criteria of remissi
PSP-activities (means ± SD) SWGC
CGI-S
PSP-social rel (means ± SD) SWGC
CGI-S
PSP-self care (means ± SD) SWGC
CGI-S
PSP-aggressive and disturbing behaviour (means ± SD) SWGC
CGI-S
PSP total score (means ± SD) SWGC
CGI-S
SWGC Schizophrenia Working Group Severity Criterion, CGI Clinical Global Impressio(n = 32) and 59.1% of schizoaffectives (n = 39) (p = 0.258).
The proportion of subjects in a state of subjective well-
being among those clinically remitted according to RSWG
criteria was 70% (n = 14) for schizophrenics (p = 0.955),
and 63.9% for schizoaffectives (n = 23) (p = 0.385); accord-
ing to CGI criteria, the proportions were 70.8% (n = 17)
and 77.4% (n = 24), respectively, for schizophrenics
(p = 0.845) and schizoaffectives (p = 0.04). Overall, the
rates of subjects who were “clinically remitted” and in
a state of “well-being” were 66.1% (n = 37) and 74.5%
(n = 41), respectively, using RSWG and CGI-S criteria.
The rates of subjects who were “clinically non-remitted”
and in a state of “absence of well-being” were 39.3%
(n = 22) and 47.4% (n = 27), respectively. Phi coefficients
were 0.056 (p = .556) and 0.227 (p = .016), respectively,
using RSWG and CGI-S criteria. Mean scores were signi-
ficantly higher at SWN subscales and total scale only
among clinically remitted when using CGI-S criteria
(Table 5), with effect sizes of a generally moderate magni-
tude. Considering the two groups of patients separately,
no statistically significant differences were found in mean
SWN total score and at all subscales between clinically re-
mitted and non-remitted schizophrenic patients using
RSWG criteria, while the only difference detected using
CGI criteria was observed for the subscale “Mental func-
tioning”, where remitted patients scored significantly
higher (p = 0.014). Likewise, in schizoaffective patients,
no statistically significant differences were detected at
SWN total score and at all subscales between clinically re-
mitted and non-remitted patients using RSWG criteria,
while using CGI criteria, significantly higher scores
(p values between <0.01 and <0.0001) were found at all
SWN subscales and total score among remitted patients.
Discussion
To our knowledge, this is the first study comparing remis-
sion evaluated by means of the Clinical Global Impression-
Schizophrenia severity scale and RSWG criteria. Indeed,tients according to different criteria
on Remitted Non-remitted Statistics(df)/Cohen’s d
1.88 (1.27) 3.20 (1.21) t(110) = −5.64, p < .0001/−1.06
1.76 (1.12) 3.28 (1.23) t(110) = −6.79, p < .0001/−1.29
2.02 (1.15) 2.86 (1.15) t(110) = −5.64, p < .0001/−0.73
1.91 (1.04) 2.95 (1.71) t(110) = −4.95, p < .0001/−0.94
0.34 (0.69) 0.80 (1.16) t(110) = −2.56, p < .012/−0.48
0.45 (0.86) 0.68 (.1,09) t(110) = −1.24, p = .218/NA
0.14 (0.44) 0.50 (0.81) t(110) = −2.89, p < .005/−0.55
0.24 (0.64) 0.40 (0.70) t(110) = −1.32, p = .191/NA
62.27 (13.65) 50.38 (14.79) t(110) = 4.43, p < .0001/0.83
64.84 (11.49) 48.11 (14.21) t(110) = 6.84, p < .0001/1.30
n Severity Criterion, NA not assessed in the absence of significant difference.
Table 5 Results at SWN scale in remitted and non-remitted patients according to different criteria
Items Criteria of remission Remitted Non-remitted Statistics(df)/Cohen’s d
SWN-mental functions (means ± SD) SWGC 16.98 (3.44) 15.79 (4.59) t(110) = 1.56, p = .121/NA
CGI-S 17.96 (3.39) 14.86 (4.12) t(110) = 4.33, p < .0001/0.826
SWN-self control (means ± SD) SWGC 17.59 (3.96) 16.21 (4.07) t(110) = 1.81, p < .073/NA
CGI-S 18.15 (3.69) 15.70 (4.06) t(110) = 3.33, p = .001/0.634
SWN-physical functions (means ± SD) SWGC 17.79 (3.53) 16.98 (3.96) t(110) = 1.13, p = 260/NA
CGI-S 18.35 (3.22) 16.46 (4.03) t(110) = −2.74, p = .007/0.521
SWN-emotional control (means ± SD) SWGC 16.71 (3.94) 16.91 (4.52) t(110) = −.245, p = 807/NA
CGI-S 17.98 (3.80) 5.68 (4.33) t(110) = −2.97, p = 004/0.566
SWN-social activities (means ± sd) SWGC 17.57 (3.15) 16.70 (4.03) t/(110) = 1.281, p = .203/NA
CGI-S 17.89 (3.40) 16.40 (3.71) t(110) = −2.21, p = .029/0.421
SWN total score (means ± SD) SWGC 86.64 (14.03) 82.59 (15.85) t(110) = 1.433, p = .155/NA
CGI-S 90.33 (13.31) 79.11 (14.64) t(110) = 4.23, p < .0001/0.808
SWGC Schizophrenia Working Group Severity Criterion, CGI Clinical Global Impression Severity Criterion, NA not assessed in the absence of significant difference.
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purpose, demonstrating that a score of 1 (very much im-
proved) at week 4 of treatment correlated with the remis-
sion criteria developed by RSWG at study endpoint. In our
sample, a very similar proportion of subjects, 50% and
49.1%, respectively, were found to be in clinical remission
according to RSWG criteria [4] and CGI severity criteria, a
result in line with other studies performed in different set-
tings adopting mostly RSWG criteria [27-29]. Moreover,
we found a highly significant correlation between the
two systems in the identification of remitters and non-
remitters; mean scores at clinical rating scales were sig-
nificantly higher among remitters evaluated by means
of both RSWG and CGI-S criteria, with a very similar
magnitude of differences in mean scores between re-
mitters and non-remitters using the two sets of criteria.
No significant differences were found in mean scores at
the majority of neurocognitive measures assessed between
remitted and non-remitted patients, both using RSWG
and CGI-S criteria. These results seem to support the hy-
pothesis of a decline in cognitive functioning independent
of clinical status, as shown recently by Shrivastava et al.
[30] in a cohort of schizophrenic patients displaying a sig-
nificant clinical improvement after 10 years of treatment.
In our study, 23 patients (20.5%) were found to be in func-
tional remission; approximately one third of clinically
remitted subjects, according to both RSWG and CGI-S
criteria, were found to be “functionally remitted”, with
an extremely large and similar proportion of patients
(approx. 91%) who were both clinically and functionally
unremitted, irrespective of remission criteria adopted.
This finding is in line with evidence reported of an incom-
plete recovery in schizophrenic disorders [1] and with the
opinion generally shared by psychiatrists that patients
affected by schizophrenia generally show impaired or
very poor levels of functioning [31]. Furthermore, ourdata demonstrate that clinical remission is related to a
similar degree of functional remission when evaluated
by means of CGI-S and RSWG criteria. As expected
from previous studies [27,28], mean PSP scores were
unfailingly significantly higher among remitters than
non-remitters. In our study, this finding was largely in-
dependent of remission criteria applied, with the same
magnitude of differences in mean scores, thus provid-
ing further confirmation of the similar performances
produced by these criteria. Further confirmation of the
validity of CGI-S criteria is provided by data relating to
the evaluation of subjective well-being. Indeed, clinical
remission evaluated according to CGI-S seems the sole
criterion to bear a significant association with subject-
ive well-being, both in terms of the percentage of sub-
jects identified as being in this state and of differences
in mean scores between remitters and non-remitters.
Prior to drawing conclusions, several limitations charac-
terizing the present study should be taken into account.
First, the sample size of the study was rather limited; sec-
ond, the study focused solely on chronic outpatients who
referred to the centre over a specific period, thus exclud-
ing patients who had moved away, refused to continue
treatment or no longer needed continuing care. Therefore,
the findings emerging from the study should be applied
only to chronic patients undergoing long-term treatment.
Additionally, as sample heterogeneity is considered one
of the main flaws of remission studies [12], the inclu-
sion in the present study of patients affected by both
schizophrenia and schizoaffective disorders should be
taken into account. However, clinical remission rates
observed were consistently similar among patients with
schizoaffective and schizophrenic disorders, independent
of remission criteria adopted. Moreover, although the pro-
portion of schizoaffective patients found to be in func-
tional remission was higher than among schizophrenics,
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tionally, rates of functionally remitted patients detected
among clinically remitted patients, both schizophrenic
and schizoaffective, independent of the remission cri-
teria adopted, were similarly higher. It should be taken
into account that the severity criterion alone, without
the duration criterion, was used in evaluating remis-
sion. Remission studies generally demonstrate how use
of the severity criterion alone is associated with higher
remission rates [12] compared to use of both severity
and duration criteria. However, as pointed out also in a
critical review [9], the majority of studies used RSWG
criteria only, neglecting duration, as this choice is often
more feasible for study design. We may assume that rates
of remission found in this study using both RSWG and
CGI criteria would be similar, although lower, even when
adopting the time component in evaluating remission. Ac-
cordingly, we hope to confirm the validity of this hypoth-
esis once data from the 2-year follow-up of the present
study become available. At present, we acknowledge that
the abovementioned limitation prevents us from drawing
any firm conclusions as to the validity of complete remis-
sion criteria.
Finally, it should be underlined how raters taking part
in this study, due to their expertise with PANSS and other
rating scales, may, at times, have evaluated the same pa-
tient, thus enhancing familiarity with patients’ symptoms
and creating a potential bias toward consensus. Moreover,
no structured interview guide, recently reported to im-
prove the accuracy of data obtained, was used in evaluat-
ing global clinical impression [32]. However, it should be
emphasized that every effort was made to avoid, whenever
possible, assessment of patients by the same resident and
that a good inter-rater reliability for CGI-SCH evaluations
was confirmed before starting the study. Thus, even in the
light of the above limitations, the evidence collected may
be of relevance in clinical practice.
As expected, the present study confirms the validity of
severity remission criteria proposed by the RSWG in de-
termining a better symptomatologic and functional pro-
file, lending further support to the findings of Van Os
et al. [10] who reported how the use of standardized re-
mission criteria in schizophrenia “had the potential to
improve documentation of clinical status in medical re-
cords, by providing an objective measure of illness
course and treatment effect that is applicable to routine
clinical care”. Moreover, the data obtained in this study
indicate how the CGI-Severity criterion may represent
an appropriate alternative to RSWG criteria, both in
pragmatic studies and in routine practice, due to the
ease of application of CGI-SCH in assessing the clinical
conditions of patients and their remission status, based
upon a rapid assessment of all dimensions of symptom-
atology in schizophrenia. Moreover, the possibility of amore user-friendly method for use in the evaluation of
remission, may contribute towards extending this ap-
proach to the routine care system, with the consequent
advantage of a more concise, and in our opinion, more
useful way of assessing outcomes of therapeutic inter-
ventions. However, it should be highlighted that although
time-consuming, the use of the entire PANSS, not limited
to selected items such as those included in RSWG criteria
[4], would seem to be better suited for research purposes,
being associated with the best performances in describing
remission [33].
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